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ABSTRACT
Repeated' tr~atment with the non-selective dopamine agonist apoJiorphine results in behavioral sensitization and enhanced dopamine synthesis in dopantlne
projection fields. To examine the role ofD2 -type dopamine receptors in modulating these
effects, the present experiment assessed the effects of repeated treatment with lthe
D2 -type agonist quinpirole on locomotor activity and dopamine synthesis. In the first
experiment, rats were treated with vehicle or one of two doses (0.3 or 3.0 mg/k~) of
quinpirole for 8 days. Daily measures oflocomotor activity revealed an initial suppression
of activity produced by quinpirole which dissipated over the 8 days of treatment. A trl.nd
for an increase in activity for 3.0 mg/kg quinpirole compared to vehicle was obtained on
day 8. Twenty-four hours after cessation of treatment, dopamine synthesis, measured as
accumulation of 3,4-dibydroxyphenylalanine (DOPA) after treatment with the DOPA
decarboxylase inhibitor NSD-1015, was enhanced in the striatum, but not nucleus\ accumbens-olfactory tubercle (NAOT) or ventral mesencephalon (VM). In Experiment 2,
rats were treated for 8 days with vehicle, 3.0 mg/kg quinpirole or the D1 antagonist ~CH
23390 (0.5 mg/kg) in a two (vehicle or quinpirole) x two (vehicle or SCH 23390) desjgn.
Quinpirole-alone treatment resulted in a reduction of the locomotor suppressant effects
of the drug. SCH 23390-alone and quinpirole-SCH 23390 combined treatment resultei! in
decreased activity compared to the vehicle control group that did not cliange across dhs.
DOPA accumulation was enhanced in the striatum and NAOT after quinpirole tr~at
ment; however, SCH 23390 had no effect. In Experiment 3, rats were treated for 10 days
with vehicle, 3.0 mg/kg quinpirole or the D 2 antagonist eticlopride (LO mg/kg) in a two
(vehicle or quinpirole) X two (vehicle or eticlopride) design. As in the first two exp:eriments, repeated quinpirole-alone treatment resulted in a redµction of the locomotor
suppressant effects of the drug; however, locomotor activity in this group was enhariced
compared to vehicle controls on day 10. Eticlopride-alone and eticlopride-quinpitole
treated rats had suppressed locomotor activity across the 10 days. DOPA accumulation
was enhanced by both repeated quinpirole and repeated eticlopride treatment in jthe
striatum and NAOT. DOPA accumulation in eticlopride-quinpirole treated rats was not
1
different from vehicle control levels in the NAOT, while no significant difference was
obtained between the eticlopride-alone and eticlopride-quinpirole groups in the striat\im.
The locomotor activity data suggest that repeated quinpirole treatment results in tolerance to the locomotor suppressant effect of the drug. Evidence for sensitization fvas
obtained in two out of three of the experiments. These results suggest that enhanced
dopamine synthesis after repeated non-selective dopamine agonist treatment is mtidu. receptors. © 1995 Wiley-Liss, Inc.
'
lated by D2-type dopamme
INTRODUCTION
Drugs that act as direct or indirect agonists for
dopamine receptors often produce a progressive enhancement of the acute behavioral effects of the drugs
following repeated treatment. This phenomenon is
© 1995 WILEY-LISS,
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Received March 21, 1994; accepted in revised form

Jan~ 31, 1995.
I

Address reprint requests to Dr. Bruce A Mattingly, Department of Psychology,
Morehead State University, Morehead, KY 40351-1689. I

Dr. Rowlett'a current address is Department of Psychiatry and Hum.an Behavior, Arthur C_ Guyton Laboratory Research Building, TI:ie University of Mississippi Medical Center, 2500 North State Street, Jackson, ¥S 39216-4505.

J.K ROWLETT ET AL.

212
2000
f/)

I-

1800

::>

1600

z

0

1400

I:
>
;=

1200

()

()
<(

z

l:'i

"'

•-•
•· - ·•

3.0 MG/KG QUINPIROLE
0.3 MG/KG QUINPIROLE
VEHICLE

O·····O

'

3.0 MG/KG QUINPIROLE
0.3 MGtKG QUINPIROLE
CJ VEHICL

c

0

"'

a~

l

,,,

:; 0
E

1000

"uu

BOO
600

<(
<(

a.

400

100

~

~
50

~

Locomotor activity
The locomotor activity data for the 8 days ofrepeated
quinpirole treatment are shown in Figure 1. As may be
seen, both doses of quinpirole produced a significant
inhibition of locomotor activity on the first treatment
day. This inhibitory effect of quinpirole, however, declined with repeated treatments. As expected, a nrixed
factorial ANOVA revealed a significant main effect of
day, F(7,252) = 8.84, P < 0.0001, and a significant
drug dose x day interaction, F(14,252) = 10.23,
P < 0.0001. To further examine the effect of repeated
quinpirole treatment on locomotor activity, an ANOVA
was performed on the day 8 data. This analysis revealed a significant effect of drug dose, F(2,36) = 4.20,
P < 0.05; however, Dunnett's tests did not reveal significant differences of the two doses compared to the
vehicle controls. These results are consistent with those
observed previously in this laboratory using the same
procedure (Mattingly et al., 1993).
DOPA accumulation
The DOPA accumulation results of Experiment 1 are
shown in Figure 2. A mixed factorial ANOVA revealed a
significant main effect of region, F(2, 72) = 209.9,
P < 0.0001 and a significant region x quinpirole dose
interaction, F(4,72) = 3.06, P < 0.05. Multiple comparisons revealed that DOPA levels in the striatum were
significantly elevated at both doses of quinpirole compared to control (Dunnett's tests, P < 0.05).
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Fig. 1. Activity counts (mean ± SEM) per 20-min session across the
8 days of treatment with quinpirole or vehicle (n = 13 rats/group).

RESULTS
Experiment 1
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and quinpirole versus vehicle treatment. The withinsubjects factors were day or brain regions. Violations of
homogeneity of variance were examined using the
Huyn-Feldt epsilon. Degrees of freedom were corrected
if the epsilon value was < 0. 75. Multiple comparisons
were made using the Dunnett's test comparing drug
groups to the vehicle control or Student's t-tests. For
the ANOVAs and multiple comparisons, the alpha level
was constrained to P .;; 0.05.
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Fig. 2. DOPA accumulation (mean percent of vehicle control in µg/
g ± percent SEM for each group) for rats treated 8 days with quinpirole or vehicle (n = 13/group). All rats were treated with NSD-1015
(100 mg/kg) on day 9 prior to dissection of the striatum, NAOT (nucleus accumbens-olfactory tubercle) and VM (ventral mesencephalon).
Note that"*" indicates a significant difference from control (Dwmett's
tests, P < 0.05).
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Fig. 3. Activity counts (mean ± SEM) per 20-min session across the
8 days of treatment with combinations of quinpirole (QUIN, 3.0 mg/
kg), SCH 23390 (SCH, 0.5 mg/kg) or vehicle (VEH; n ~ 12 rats/group).

Experiment 2
Locomotor activity
The locomotor activity data for the 8 days ofrepeated
quinpirole-SCH 23390 treatment are shown in Figure
3. As may be seen in this figure, SCH 23390 treatment
significantly suppressed locomotor activity and prevented the progressive increase in quinpirole-induced
locomotor activity. A mixed factorial ANOVA revealed
the following significant between-subjects effects: quinpirole main effect, F(l,44) = 15.22, P < 0.001; SCH
23390 main effect, F(l,44) = 272.27, P < 0.0001;
quinpirole x SCH 23390 interaction, F(l,44) = 22.65,
P < 0.0001. The following effects involving repeated measures were significant: day main effect, F(7,308) = 13. 77,
P < 0.0001; quinpirole x day interaction, F(7,308) =
25.87, P < 0.0001; SCH 23390 x day interaction,
F(7,308) = 10.69, P < 0.0001; quinpirole x SCH 23390
x day interaction, F(7,308) = 17.68, P < 0.0001. The
significant overall interaction likely reflects the grad-
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Fig. 4. DOPA accumulation (mean percent-of vehicle control in µg/
g ± percent SEM for each group) for rats treated 8 days with combinations of quinpirole (QUIN, 3.0 mg/kg), SCH 23390 (SCH, 0.5 mg/kg) or
vehicle (VEH; n = 12/group). All rats were treated with NSD-1015
(100 mWk:g) on day 9 prior to dissection of the striatum, NAOT (nu-

cleus accumbens-olfacto:ry tubercle) and VM (ventral mesencephalon).
Note that"*" indicates a significant difference from control (Dunnett's
test,P < 0.05).

ual increase to control levels by rats treated with vehicle and quinpirole, while all other groups did not
change across days. An ANOVA performed on day 8
revealed a significant main effect of SCH 23390,
F(l,44) = 194.42, P < 0.0001. The main effect of quinpirole treatment approached, but did not achieved significance, F(l,44) = 3.77, P = 0.0586. Tbe interaction
of quinpirole and SCH 23390 and all multiple comparisons on day 8 were not significant. These findings also
are consistent with our previous study (Mattingly et al.,
1993).
DOPA accumulation
Tbe DOPA accumulation results for the three brain
regions are shown in Figure 4. A mixed factorial
ANOVA revealed significant main effects of quinpirole
treatment, F(l,44) = 14.08, P < 0.001, and region,
F(2,88) = 385.41, P < 0.0001 (epsilon = 0.62). The interaction ofregion x quinpirole treatment also was significant, F(2,88) = 12.32, P < 0.001 (epsilon= 0.62).
No main effect or interaction involving SCH 23390
treatment was significant, suggesting that SCH 23390
co-treatment was without effect on DOPA accumulation. Indeed, multiple comparisons revealed that DOPA
levels in the vehicle-quinpirole and SCH 23390-quinpirole treated rats were significantly greater than control
in both striatumand NAOT (Dunnett's tests, P < 0.05).
Comparisons of DOPA levels in striatum and NAOT of
the vehicle-quinpirole and SCH 23390-quinpirole rats
revealed no significant difference (Student's t-test,
p > 0.05).
Experiment 3
Locomotor activity
Tbe locomotor activity data for the 10 days of repeated quinpirole-eticlopride treatment are shown in
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Fig. 5. Activity counts (mean± SEM) per 2()..min session across
the 10 days of treatment with combinations of qUinpirole (QUIN, 3.0
mg/kg), eticlopride (ETIC, 1.0 mg/kg) or vehicle](VEH; n = 12 rats/
group).
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Figure 5. Like SCH 23390 treatment, eticlopride
treatment inhibited locomotor activity and blocked the progressive increase in quinpirole-induce~ locomotor activity. A mixed factorial ANOVA revealed a significant
between-subjects main effect of eticlopride, F(l,44) =
98.55, p < 0.0001, only. Tbe following effects involving
repeated measures were significant: day main effect,
F(9,396) = 4.95, P < 0.0001; quinpirolJ x day interac'
tion, F(9,396) = 13.36, P < 0.0001; eticlopride
x day
interaction, F(9,396) = 3.35, P < O.OOl; quinpirole x
eticlopride x day interaction, F(9,39G) = 5.25, P <
0.0001. An ANOVA performed on day 10 revealed a
significant main effect of quinpirole,' F(l,44) = 7.77,
P < 0.01, and of eticlopride, F(l,44) = 41.48, P <
0.0001. The interaction of quinpirole and SCH 23390 on
day 10 was not significant. Dunnett's tests showed that
the group treated with quinpirole and vehicle had significantly greater locomotor activity counts than the
vehicle control group (P < 0.05). Thus~ after 10 daily
treatments, quinpirole significantly increased locomotor activity relative to vehicle control rats. In addition,
both groups treated with eticlopride ~hawed significantly lower locomotor activity couhts than the controls
(P < 0.05).
'
DOPA accumulation
The DOPA accumulation results for ,the three brain
regions are shown in Figure 6. A mixed factorial
ANOVA revealed a significant main ~!feet of region,
F(2,86) = 87.72, P < 0.0001 (epsilon =i0.68). No other
main effects or interactions were significant. The interaction of quinpirole treatment and eticlopride treatment approached, but did not achie~e significance,
F(l,46) = 3.85,P = 0.056.AsinExperii\ient2, multiple
comparisons showed that DOPA accumhlation was significantly increased in vehicle-quinpirble treated rats
compared to controls iu both the striatum and NAOT
(Dunnett's tests, P < 0.05). Compariso!is between controls and the eticlopride-quinpirole tl-eated rats re-
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Fig. 6. DOPA accumulation (mean percent of vehicle control in µ.gl
g ± percent SEM for each group) for rats treated 10 days with combinations of quinpirole (Q, 3.0 mg/kg), eticlopride (E, 1.0 mg/kg) or vehicle (n = 12/group). All rats were treated with NSD-1015 (100 mg/kg)

on day 11 prior to dissection of the striatum, NAOT (nucleus accumbens-olfactory tubercle) and VM (ventral mesencephalon). Note that

"*" indicates a significant difference from control (Dunnett's test,
p < 0.05).

vealed a significant increase in DOPA accumulation for
the striatum, but not NAOT (Dunnett's tests, P < 0.05).
However, DOPA levels also were elevated in the eticlopride-vehicle treated rats compared to controls in both
striatum and NAOT (Dunnett's tests, P < 0.05). Additional t-tests comparing eticlopride-vehicle and eticlopride-quinpirole rats revealed no significant differences.
DISCUSSION
Consistent with our previous findings, acute quinpirole treatment resulted in dose-dependent suppression
of locomotor activity (Mattingly et al., 1993). With repeated treatment, the locomotor suppressant effect of
quinpirole diminished until the activity levels of quinpirole-treated rats were equal to (Experiments 1 and 2),
or greater than (Experiment 3), vehicle-treated rats.
This progressive increase in quinpirole-induced locomotor activity is consistent with our previous work
(Mattingly et al., 1993). Within the present paradigm,
whether this increase in quinpirole-induced activity
should be interpreted as tolerance or sensitization is
unclear. However, previous work in other laboratories
using longer test intervals has demonstrated a biphasic
inhibitory-excitatory effect of quinpirole following a
single administration and a clear sensitization effect
with repeated administration (Eilam et al., 1992). Similarly, the direct D2 -type dopamine receptor agmrist
bromocryptine also depressed locomotor activity when
first presented, but resulted in locomotor sensitization
with repeated treatment (Hoffinan and Wise, 1992).
Thus, the lack of a clear sensitization effect in the
present study may be related to the relatively short
duration of the activity test used.

The major finding of the present experiment was that
repeated quinpirole treatment resulted in enhanced
DOPA accumulation in the striatum and NAOT. Thus,
consistent with previous studies with repeated apomorphine treatment (Rowlett et al., 1991, 1993; Vaughn et
al., 1990), repeated stimulation of D2 -type dopamine
receptors resulted in enhanced dopamine synthesis in
dopamine terminal fields. We have previously noted
that enhanced dopamine synthesis in the NAOT following repeated apomorphine treatment may be a relatively weak effect compared to the effect obtained in the
striatum (Rowlett et al., 1993). Some evidence for a
similar relationship between dopamine synthesis in the
NAOT and striatum following repeated quinpirole was
obtained in the present series of experiments. Thus,
while striatal dopamine synthesis was clearly increased in all three experiments, the enhanced dopamine synthesis effect was obtained in the NAOT only in
Experiments 2 and 3, but not Experiment 1. Moreover,
the magnitude of the percentage increase in DOPA accumulation in the NAOT varied from experiment to
experiment, whereas the magnitude of the percentage
increase in DOPA accumulation in the striatum was
relatively consistent across experiments. The reason
for this difference in DOPA accumulation results between the striatum and NAOT is not clear; however,
the results may reflect a differential modulation of
dopamine synthesis between the striatum and NAOT.
Experiment 2 demonstrated that co-administration
of the selective D1 receptor antagonist SCH 23390 did
not block the enhanced dopamine synthesis effect produced by repeated quinpirole treatment. This finding is
consistent with modulation of dopamine synthesis by
D2 autoreceptors, and not D1-type receptors (Brown et
al., 1985; Wachtel et al., 1989; White and Wang, 1984b;
Wolf and Roth, 1990). Further, this finding is consistent with a previous study which indicated that D 1 receptor stimulation does not result in enhanced dopamine synthesis (Rowlett et al., 1993). The results of
Experiment 3 suggest that the D2 -type antagonist eticlopride blocked the enhanced dopanrine synthesis effect produced by quinpirole in the NAOT. This finding
is consistent with eticlopride's high selectivity for D2 type receptors and provides further evidence for D2 type modulation of the enhanced dopamine synthesis
effect. In the striatum, there was no significant difference in DOPA accumulation between the eticlopridevehicle and eticlopride-quinpirole treated rats, also
suggestive ofa blockade of the enhanced dopamine synthesis effect produced by repeated quinpirole treatment. However, dopamine synthesis was enhanced following repeated eticlopride treatment in both striatum
and NAOT. This finding was unexpected and the reason for this enhanced dopamine synthesis effect following repeated eticlopride treatment is not clear. One possibility is that eticlopride was present in the brain at
the time ofNSD-1015 adnrinistration. Support for this
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notion comes from previous findings that acute eticlopride treatment produces enhanced DOPA accumulation (Tyler and Galloway, 1992) and Dz-type antagonists produce enhanced dopamine neuron impulse flow
(White and Wang, 1984b). Irideed, O'Dell et al. (1993)
reported that repeated eticlopride treatment (four injections at 2-h intervals) resulted in enhanced striatal
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dopamine release, measured with in vivo microdialysis.
It is also possible, however, that repeated eticlopride
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treatment resulted in some neurochemical alteration
that indirectly enhanced dopamine synthesis. For example, repeated eticlopride treatment results in upregulation of Dz-type receptors (LaHoste and Marshall,
1991); however, up-regulation of autoreceptors would
likely result in decreased dopamine synthesis. These
issues clearly require further investigation; nevertheless, evidence for a blockade of repeated quinpiroleinduced enhanced dopamine synthesis in the NAOT
clearly was obtained, in spite of the increase in DOPA
accumulation produced by repeated eticlopride alone.
The observation of an enhanced dopamine synthesis
effect after repeated quinpirole treatment is consistent
with the notion that repeated non-selective dopamine
agonist treatment produces a reduction in dopamine
autoreceptor sensitivity (e.g., Henry et al., 1989; Jeziorski and White 1989; Rebec and Lee, 1982; Rowlett et al.,
1991, 1993; White and Wang, 1984a). Indeed, the results of this study combined with our previous findings
indicate that the enhanced dopamine synthesis effect
observed after repeated apomorphine treatment likely
is modulated by Dz-type autoreceptors. Taken together,
our findings are consistent with an hypothesis for the
development of behavioral sensitization advanced by
Henry et al. (1989). Specifically, these authors suggested that repeated cocaine treatment results in subsensitivity of impulse-regulating autoreceptors followed by terminal field D 1 receptor supersensitivity.
The results of the present study and our previous study
(Mattingly et al., 1993) showing cross-sensitization of
quinpirole and apomorphine that was blocked by a D1
antagonist are consistent with this hypothesis. Thus,
repeated quinpirole treatment may result in autoreceptor subsensitivity, which in turn results in enhanced
dopamine release and consequent D 1 stimulation. In
the present study, blockade of D1 receptors had no effect on dopamine synthesis after repeated quinpirole
treatment. Therefore, autoreceptor subsensitivity may
occur without the development oflocomotor sensitization.
Recent molecular biological studies have identified at
least five subtypes of dopamine receptors (see Schwartz
et al., 1993). Of these subtypes, quinpirole binds with
higher affinity to the D3 subtype than to the D2 or D4
subtypes, whereas apomorphine is relatively non-selective for the Dz subtypes (Levesque et al., 1992; Sokoloff
et al., 1990; Van Toi et al., 1991). Based upon this affinity difference, it may be speculated that the enhanced

dopanrine synthesis effect observed ~fter repeated
quinpirole and apomorphine treatment may involve repeated D3 · receptor stimulation. However, it is not
known if the doses used in the present study differentiate between the two subtypes. In addition, the most
robust augmentation of dopamine synth~sis occurred in
the striatum, an area that has low levels of D3 mRNA,
as well as low binding levels of the D3 !ii;'and [3H]7-0HDPAT (Levesque et al., 1992; Schwartz et al., 1993;
Sokoloff et al., 1990). Thus, the role of D 3 versus D2
receptors in the ellhanced dopamine sJ,nthesis effect
remains to be determined.
I
Finally, another possible mechanisiJi of enhanced
dopamine synthesis following repeated apomorphine
treatment involves an alteration of tyrpsine hydroxyIase activity. Apomorphine, in addition to having
dopamine receptor binding properties, also may be carried into dopamine neurons where it inhibits tyrosine
hydroxylase activity directly at the pt~ridine cofactor
site (Laschinski et al., 1984). Based on tHe results of the
present study, however, this effect of ap~morphine may
not be involved in the enhanced dopaicine synthesis
effect because quinpirole does not have alcatechol structure (Titus et al., 1983). Thus, any changes in tyrosine
hydroxylase activity following repeated Dz agonist
treatment are likely due to an indirect iJ\fluence on the
enzyme rather than direct drug-induced!changes at the
1
pteridine cofactor site.
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